Canada’s Drug Agency recommends funding lecanemab for early-stage Alzheimer’s disease

TORONTO — Canada’s Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer’s disease if patients meet certain conditions…